The mass tort landscape in 2026 is defined by a handful of cases commanding the litigation system. Johnson & Johnson’s talcum powder litigation dominates by sheer case volume with 67,100 pending claims, followed by hernia mesh complications at 24,000 cases and aqueous film-forming foam (AFFF) contamination at 15,200 cases. These three matters alone account for over 106,000 of the 199,000 pending cases tracked across federal multi-district litigations (MDLs) as of March 2026. Across all mass tort categories, the federal court system carries 704,000 total filed cases, and 2026 is expected to distribute more than $25 billion in class action settlements.
What distinguishes 2026 litigation is the velocity of newer cases. The GLP-1 weight-loss drug litigation—driven by lawsuits against manufacturers of Ozempic, Wegovy, and Trulicity—has grown 130 percent year-over-year with 3,100 pending cases. At the same time, high-profile cases like Camp Lejeune water contamination and the Paragard IUD litigation are entering critical verdict phases that will reshape settlement valuations across the entire mass tort docket. The combination of aging legacy cases, emerging high-growth dockets, and record settlement distributions makes 2026 a pivotal year for mass tort resolution.
Table of Contents
- How Many Cases Are Driving Mass Tort Litigation in 2026?
- The Largest Mass Tort Cases by Pending Case Count
- The Fastest-Growing Mass Tort Litigation: GLP-1 Weight-Loss Drugs
- Critical Cases Entering Verdict Phases in 2026
- Litigation on Emerging Health Claims
- Social Media Addiction and Emerging Defendant Categories
- Class Action Settlement Distributions and 2026 Payout Expectations
How Many Cases Are Driving Mass Tort Litigation in 2026?
The scale of pending mass tort cases provides context for understanding litigation capacity and settlement timelines. As of March 2026, 199,000 cases are active within federal MDLs, representing a consolidation mechanism that allows thousands of similar claims to move through the courts efficiently. This concentration of cases in MDLs—whether in torts involving pharmaceuticals, medical devices, environmental contamination, or consumer products—enables judges to establish coordinated discovery schedules, evidentiary rulings, and bellwether trial procedures that apply across multiple cases.
The total universe of mass tort filings extends beyond MDLs. Across all categories of mass torts, including those handled in state courts and non-consolidated federal dockets, 704,000 cases have been filed. This distinction matters because non-MDL cases often move at different speeds and may settle on different terms than coordinated cases. For instance, a talc plaintiff filing in state court in New Jersey may negotiate a settlement based on local jury propensities, while the same plaintiff’s case could be consolidated into the federal MDL serving judges in New Jersey federal court with a different settlement framework.
The Largest Mass Tort Cases by Pending Case Count
Johnson & Johnson’s talcum powder litigation represents the highest-volume single tort claim in the U.S. legal system. The 67,100 pending cases allege that asbestos-contaminated talc caused mesothelioma, lung cancer, and ovarian cancer. In late 2025, a jury awarded a single plaintiff over $1.5 billion in damages, an outcome that signals to other claimants and their attorneys that individual verdicts can reach substantial levels. This high verdict amount does not necessarily predict settlement values for the broader docket, since juries in specific jurisdictions may award different amounts based on local factors, and J&J’s bankruptcy protection status complicates settlement mechanics. The second and third largest categories by case count are hernia mesh complications (24,000 cases) and AFFF firefighting foam contamination (15,200 cases).
Hernia mesh claims allege that polypropylene mesh implants eroded, perforated adjacent tissue, or became chronically infected. AFFF cases involve aqueous film-forming foams used by military bases, airports, and firefighting facilities—the foam contains “forever chemicals” (PFAS compounds) that persist in soil and groundwater. Both dockets have produced significant settlements over prior years; the question for 2026 is whether remaining cases will command higher valuations as evidence of long-term harms accumulates or whether settlement pressure will lead to lower per-case values as older claimants seek final resolution. Hair relaxer lawsuits represent the fourth major category with 11,400 pending cases. These claims allege that chemical hair relaxers—products used primarily by Black women—increase the risk of uterine cancer, ovarian cancer, and other cancers through repeated scalp exposure. Unlike talc or hernia mesh, the hair relaxer litigation is more recent, meaning evidence is still developing and juries have limited prior verdict data to anchor expectations. This creates uncertainty for both plaintiffs and defendants about settlement fair value.
The Fastest-Growing Mass Tort Litigation: GLP-1 Weight-Loss Drugs
The most dramatic growth in mass tort litigation entering 2026 concerns GLP-1 receptor agonist drugs used for diabetes management and weight loss. Products including Ozempic, Wegovy (semaglutide), and Trulicity (dulaglutide) face allegations that manufacturers failed to adequately warn consumers about serious side effects. The GLP-1 MDL has grown 130 percent year-over-year and now contains 3,100 pending cases. The rapid accumulation of claims reflects both the enormous patient population using these drugs and newly reported adverse events.
Plaintiffs allege gastroparesis (severe stomach paralysis), vision-related injuries, and thyroid complications resulting from GLP-1 use. The challenge for litigants is that these drugs were approved by the FDA, labeling includes warnings about gastrointestinal effects, and the mechanism by which weight loss itself might cause injury remains contested. Nonetheless, the sheer volume of cases and ongoing clinical evidence about long-term side effects position the GLP-1 docket as a central litigation trend for 2026. Settlement negotiations are expected to intensify as bellwether trial results begin to emerge.
Critical Cases Entering Verdict Phases in 2026
The Paragard IUD litigation has advanced to bellwether trial proceedings in 2026, with trials scheduled in the Georgia MDL. Paragard is a copper intrauterine device marketed as a long-term contraceptive. Plaintiffs allege that the device’s plastic arms can break or fragment during removal, causing pain, infection, uterine perforation, and other injuries. The bellwether trial process—where a small number of representative cases go to trial first—will produce jury verdicts that inform settlement negotiations for thousands of remaining cases. If juries award substantial damages in the Georgia trials, settlement values across the docket are likely to rise sharply. Camp Lejeune water contamination represents one of the largest mass torts in U.S.
history. The North Carolina military base contaminated drinking water with trichloroethylene (TCE), benzene, and other chemicals for decades. Thousands of former residents and military personnel filed claims alleging cancer, birth defects, and neurological disease. In 2026, the first bench trial verdicts—decided by judges rather than juries—are expected. These verdicts will establish valuation benchmarks for the docket and may accelerate settlement negotiations. The Camp Lejeune case is notable because it involves government liability rather than corporate defendants, affecting how damages are calculated and paid.
Litigation on Emerging Health Claims
Acetaminophen (Tylenol) litigation centers on allegations that prenatal exposure to acetaminophen increases the risk of autism spectrum disorder (ASD) and ADHD in children. The U.S. Court of Appeals for the Second Circuit signaled in late 2025 that it may revive acetaminophen litigation that had been dismissed. If the appellate court revives the claims, a substantial new docket could materialize in 2026. The barrier to these cases is scientific proof—establishing that acetaminophen caused specific neurodevelopmental injury in a particular child requires epidemiological evidence and expert testimony.
Courts have been skeptical of causation arguments when the alleged agent (acetaminophen) has been used by millions of pregnant women without universal adverse outcomes. Glyphosate (Roundup) lawsuits, brought against Bayer following its acquisition of Monsanto, allege that the herbicide caused non-Hodgkin’s lymphoma and other cancers. Tens of thousands of plaintiffs filed claims. Early settlements and verdicts have produced variable results; some juries found Bayer liable while others rejected causation. The 2026 trajectory for Roundup litigation depends on additional trial outcomes and the path of appellate review. A limitation of glyphosate cases is that Bayer has faced substantial liability exposure through prior settlements, potentially constraining additional settlement value for remaining claimants.
Social Media Addiction and Emerging Defendant Categories
A newly created MDL designated MDL 3047 consolidates social media addiction cases in the Northern District of California. The docket contains 85 pending cases alleging that technology companies—including Meta/Facebook, TikTok, YouTube, and others—deliberately designed features to exploit adolescents’ developing brains, creating psychological dependence and driving increased social media use. Plaintiffs allege harm including anxiety, depression, sleep disruption, and eating disorders. The social media litigation represents a novel legal frontier.
Unlike pharmaceutical or medical device cases, there is no FDA-approved product or established regulatory warning label. The defendant companies argue that their platforms provide social connection and expression, and that parents bear responsibility for monitoring children’s use. The 2026 litigation will likely focus on discovery of internal company documents concerning user engagement algorithms and adolescent vulnerability. Settlement prospects remain uncertain because the legal theories are novel and damages quantification is complex.
Class Action Settlement Distributions and 2026 Payout Expectations
Over $25 billion in class action settlement distributions are expected across 2026, reflecting both new settlements and payments from previously negotiated deals. The largest single settlement of 2026 is the insulin pricing settlement, which established a $780 million fund for consumers who purchased insulin products over a specified time period.
Additional significant settlements include the Google/YouTube Kids privacy violation ($30 million), the Cencora data breach ($40 million), and the Sutter Health MyHealthOnline privacy settlement ($21.5 million, with California residents eligible for up to $90 per person). BIPA (Biometric Information Privacy Act) cases—primarily involving facial recognition and fingerprint scans—have produced settlements averaging $200 to $1,500 per claimant.